MétaCan
Menu
Back to cohort
Record W4409232946 · doi:10.1002/pst.70014

Chauhan Weighted Trajectory Analysis of Combined Efficacy and Safety Outcomes for Risk–Benefit Analysis

2025· article· en· W4409232946 on OpenAlexaff
Utkarsh Chauhan, Daylen Mackey, John R. Mackey

Bibliographic record

VenuePharmaceutical Statistics · 2025
Typearticle
Languageen
FieldEconomics, Econometrics and Finance
TopicHealth Systems, Economic Evaluations, Quality of Life
Canadian institutionsUniversity of AlbertaUniversity of Calgary
Fundersnot available
KeywordsSample size determinationMedicineClinical trialConfidence intervalStatisticsClinical endpointComputer scienceMathematicsInternal medicine

Abstract

fetched live from OpenAlex

Analyzing and effectively communicating the efficacy and toxicity of treatment is the fundamental basis of risk-benefit analysis (RBA). There is a need for more efficient and objective tools. We apply Chauhan Weighted Trajectory Analysis (CWTA) to perform RBA with superior objectivity, power, and ease of communication. We used CWTA to perform 1000-fold simulations of RCTs using ordinal endpoints that captured both treatment efficacy and treatment toxicity. RCTs were stochastically generated with 1:1 allocation at defined sample sizes and hazard ratios. We first studied the simplest case simulation of 3 levels each of toxicity and efficacy (a 3 × 3 matrix). We then simulated the general case of the advanced cancer trial, with efficacy graded by five RECIST 1.1 health statuses and toxicity graded by the six-point CTCAE scale to create a 6 × 5 matrix. Finally, the 6 × 5 matrix model was applied to a real-world dose escalation phase I trial in advanced cancer. Simulations in both the 3 × 3 simplest case matrix and the 6 × 5 advanced cancer matrix confirmed our hypothesis that drugs with both superior efficacy and toxicity profiles synergize for greater statistical power with CWTA RBA than either signal alone. The CWTA RBA 6 × 5 matrix meaningfully reduced sample size requirements over CWTA efficacy-only analysis. Despite a small sample size, application of the matrix to each of the seven cohorts of the dose finding phase I clinical trial provided objective and statistically significant validation for the dose subjectively selected by the trialists. CWTA RBA, by incorporating both drug efficacy and the trajectory of drug toxicity, provides a single test statistic and summary plot that analyzes, visualizes, and effectively communicates the risk-benefit assessment of a clinical trial. CWTA RBA requires fewer patients than CWTA efficacy-only analysis when the experimental drug is both more effective and less toxic. Our results show CWTA RBA has the potential to aid the objective and efficient assessment of new therapies throughout the drug development pathway. Furthermore, its distinct advantages over competing tests in visualizing and communicating risk-benefit will assist regulatory review, clinical adoption, and understanding of therapeutic risks and benefits by clinicians and patients alike.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.047
metaresearch head score (Gemma)0.138
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: Methods · Consensus signal: none
Study designCandidate signal: Theoretical or conceptual · Consensus signal: none
GenreCandidate signal: Methods · Consensus signal: Methods
Teacher disagreement score0.953
Threshold uncertainty score0.251

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0470.138
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0030.004
Bibliometrics0.0040.002
Science and technology studies0.0010.002
Scholarly communication0.0020.002
Open science0.0020.003
Research integrity0.0020.004
Insufficient payload (model declined to judge)0.0090.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.236
GPT teacher head0.481
Teacher spread0.245 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designTheoretical or conceptual
DomainMethods
GenreMethods

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venuePharmaceutical StatisticsSame topicHealth Systems, Economic Evaluations, Quality of LifeFrench-language works237,207